Description: <b>Cinnamon</b> is a spice from inner bark from several tree species.<br>
Cinnamon refers primarily to bark extracts from Cinnamomum verum (Ceylon cinnamon) and Cinnamomum cassia. Bioactive constituents include cinnamaldehyde, cinnamic acid derivatives, procyanidins, and polyphenols. In cancer models, cinnamon extracts and cinnamaldehyde are most frequently reported to exert anti-proliferative, pro-apoptotic, anti-inflammatory, and anti-angiogenic effects. Mechanistic themes include suppression of NF-κB and PI3K/AKT signaling, modulation of MAPK pathways, induction of mitochondrial apoptosis, and context-dependent ROS elevation in tumor cells. Some studies report inhibition of HIF-1α and glycolytic signaling, though cinnamon is not a direct enzymatic Warburg inhibitor. Effects vary substantially depending on species (Ceylon vs Cassia), preparation (aqueous vs ethanol extract), and dose. Human oncology data remain limited and largely preclinical.<br>
<br>
-Cinnamaldehyde (CA), an active compound derived from the natural plant cinnamon. CA is an aromatic aldehyde compound, constituting approximately 65% of cinnamon extract<br>
- See also <a href="https://nestronics.ca/dbx/tbResList.php?qv=95">HCA</a>, a derivative of CA<br>
<br>
Biological activity, cinnamaldehyde from Ceylon cinnamon:<br>
Antimicrobial activity: 10-50 μM<br>
Antioxidant activity: 10-100 μM<br>
Anti-inflammatory activity: 20-50 μM<br>
Anticancer activity: 50-100 μM<br>
Cardiovascular health: 20-50 μM<br>
<br>
5 g of Ceylon cinnamon might contain roughly between 30 mg and 150 mg of cinnamaldehyde, with an approximate mid-range estimate of about 70 mg.<br>
Assuming a moderate supplemental intake 50–200 mg of cinnamaldehyde, peak plasma levels might be anticipated in the vicinity of 1–10 μM.<br>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Suppression of inflammatory and survival signaling, especially NF-κB, AP-1, COX-2, PI3K/AKT, and related anti-apoptotic programs.</li>
<li>Induction of mitochondrial apoptosis and cell-cycle arrest in cancer models.</li>
<li>Anti-metastatic and anti-invasive effects linked to glycolysis/HK2 suppression, migration inhibition, and EMT-related signaling changes.</li>
<li>Anti-angiogenic activity through VEGF/VEGFR2/HIF-1α and downstream MAPK signaling modulation.</li>
<li>Redox modulation, with antioxidant/NRF2 activation in normal-cell stress contexts but ROS elevation and apoptosis in some tumor models.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Cinnamon is compositionally variable; cinnamaldehyde is lipophilic, rapidly absorbed and metabolized, and systemic exposure after oral intake is likely much lower than many in-vitro anticancer concentrations. Extract formulation, species, dose, food matrix, and first-pass metabolism materially affect exposure.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many anticancer studies use extract concentrations or cinnamaldehyde levels that may exceed achievable free systemic exposure after ordinary oral intake. Local gastrointestinal exposure may be more plausible than systemic tumor exposure.</p>
<p><b>Clinical evidence status:</b> Preclinical for oncology. Cinnamon has human RCT/meta-analysis literature mainly in metabolic/inflammatory endpoints, but no established clinical anticancer indication. Translational constraints include variable extract chemistry, cassia coumarin hepatotoxicity risk, CYP/herb-drug interaction potential, and uncertain tumor-achievable exposure.</p>
<h3>Cinnamon Cancer Mechanism Table</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>NF-κB AP-1 inflammatory survival signaling</td>
<td>NF-κB ↓; AP-1 ↓; COX-2 ↓; Bcl-2 family survival tone ↓</td>
<td>Inflammatory tone ↓</td>
<td>R, G</td>
<td>Anti-inflammatory and anti-survival signaling</td>
<td>Core mechanism for cinnamon extract and cinnamaldehyde; model-dependent but repeatedly reported.</td>
</tr>
<tr>
<td>2</td>
<td>PI3K AKT mTOR growth signaling</td>
<td>PI3K/AKT ↓; proliferation ↓; apoptosis ↑</td>
<td>↔ or stress protection ↑</td>
<td>R, G</td>
<td>Growth-signal suppression</td>
<td>Most relevant for cinnamaldehyde-rich preparations; linked to colorectal and other cancer models.</td>
</tr>
<tr>
<td>3</td>
<td>Mitochondrial apoptosis</td>
<td>Bax ↑; Bcl-2 ↓; mitochondrial dysfunction ↑; caspase activation ↑</td>
<td>↔ at lower exposure; cytotoxicity risk at high exposure</td>
<td>G</td>
<td>Apoptotic induction</td>
<td>Central anticancer mechanism but often requires concentrations above dietary exposure.</td>
</tr>
<tr>
<td>4</td>
<td>Glycolysis and HK2 driven invasion</td>
<td>HK2 ↓; G6P/F6P production ↓; migration ↓; invasion ↓</td>
<td>↔</td>
<td>G</td>
<td>Anti-metastatic metabolic suppression</td>
<td>Mechanistically important for metastatic dissemination models; not a broad direct Warburg enzyme inhibitor claim.</td>
</tr>
<tr>
<td>5</td>
<td>VEGF VEGFR2 HIF-1α angiogenesis axis</td>
<td>VEGF ↓; HIF-1α ↓; tumor angiogenesis ↓</td>
<td>Angiogenesis ↑ in repair contexts; VEGF-stimulated pathological signaling may be ↓</td>
<td>R, G</td>
<td>Context-dependent angiogenesis normalization</td>
<td>Direction differs by context: anti-angiogenic in tumor models, but potentially pro-repair in normal tissue wound-healing/endothelial recovery settings.</td>
</tr>
<tr>
<td>6</td>
<td>ROS redox stress</td>
<td>ROS ↑ and apoptosis ↑ in some tumor models (dose-dependent)</td>
<td>ROS ↓ or antioxidant response ↑ at lower exposure</td>
<td>P, R</td>
<td>Context-dependent redox modulation</td>
<td>Not simply antioxidant or pro-oxidant; direction depends on compound, dose, exposure time, and cell stress state.</td>
</tr>
<tr>
<td>7</td>
<td>NRF2 antioxidant response</td>
<td>NRF2 ↑ may be protective or resistance-relevant (context-dependent)</td>
<td>NRF2 ↑; cytoprotective gene expression ↑</td>
<td>R, G</td>
<td>Stress-response activation</td>
<td>Important safety/normal-cell protection axis; in cancer it may be double-edged if persistent NRF2 supports survival.</td>
</tr>
<tr>
<td>8</td>
<td>Cell-cycle regulation</td>
<td>G1 or G2/M arrest ↑; cyclin/CDK signaling ↓</td>
<td>↔</td>
<td>G</td>
<td>Cytostasis</td>
<td>Secondary to upstream growth and stress signaling changes.</td>
</tr>
<tr>
<td>9</td>
<td>MAPK stress signaling</td>
<td>JNK/p38 modulation ↑; ERK modulation mixed</td>
<td>↔ or inflammatory MAPK ↓</td>
<td>P, R</td>
<td>Signal reprogramming</td>
<td>Direction varies by model and stimulus; best treated as contextual rather than primary.</td>
</tr>
<tr>
<td>10</td>
<td>Clinical Translation Constraint</td>
<td>Systemic exposure uncertain; in-vitro dose gap likely</td>
<td>Cassia coumarin hepatotoxicity risk; CYP interaction potential</td>
<td>G</td>
<td>Translation limitation</td>
<td>Ceylon cinnamon is preferred for repeated higher intake because cassia generally has higher coumarin content.</td>
</tr>
</table>
<p><small>
TSF: P = 0–30 min (redox and early signaling effects), R = 30 min–3 hr (acute pathway modulation), G = >3 hr (apoptosis, angiogenesis, phenotype changes).
</small></p>